case series: thrombocytopenia improvement with transition of intravenous epoprostenol to intravenous treprostinil

被引：0
|
作者：
Kooda, Kirstin [1 ]
Armon, Jeff [2 ]
Ou, Narith [3 ]
机构：
[1] Mayo Clin Hosp Rochester, Dept Pharm Serv, Rochester, MN USA
[2] Mayo Clin, Dept Pharm, Rochester, MN USA
[3] Mayo Clin Hosp, Rochester, MN USA
来源：
PHARMACOTHERAPY | 2017年 / 37卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
509
引用
收藏
页码：E227 / E228
页数：2
相关论文
共 50 条
  • [1] Transition from Intravenous Epoprostenol to Intravenous Treprostinil in a Portopulmonary Hypertension Patient with Thrombocytopenia
    Kusumoto, Mie
    Araki, Masaru
    Nagata, Yasufumi
    Hayashi, Atsushi
    Tsuda, Yuki
    Otsuji, Yutaka
    JOURNAL OF CARDIAC FAILURE, 2015, 21 (10) : S187 - S187
  • [2] Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension
    Gomberg-Maitland, M
    Tapson, VF
    Benza, RL
    McLaughlin, VV
    Krichman, A
    Widlitz, AC
    Barst, RJ
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 172 (12) : 1586 - 1589
  • [3] Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil
    Ivy, D. Dunbar
    Claussen, Lori
    Doran, Aimee
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (05): : 696 - 698
  • [4] Multicenter experience with the rapid transition to intravenous treprostinil from epoprostenol in pulmonary arterial hypertension
    Shapiro, Shelley
    Waxman, Aaron
    Schilz, Robert
    Strootman, Deb
    Rollins, Kristan
    Feldman, B. Jeremy
    CHEST, 2007, 132 (04) : 635S - 635S
  • [5] Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension
    Sitbon, Olivier
    Manes, Alessandra
    Jais, Xavier
    Pallazini, Massimiliano
    Humbert, Marc
    Presotto, Luis
    de Nillette, Louis
    Zaccardelli, Divid
    Davis, Gillian
    Jeff, Roger
    Simonneau, Gerald
    Galie, Naareno
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2007, 49 (01) : 1 - 5
  • [6] Transition protocol from subcutaneous treprostinil to intravenous epoprostenol in deteriorating patients with pulmonary arterial hypertension
    Mouratoglou, Sophia Anastasia
    Patsiala, Anthoula
    Feloukidis, Christos
    Karvounis, Haralambos
    Giannakoulas, George
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 306 : 187 - 189
  • [7] Thrombocytopenia associated nvith chronic intravenous epoprostenol therapy
    Hargett, CW
    Ahearn, GS
    Krichman, AM
    Ward, VR
    Thoma, K
    Tapson, VF
    CHEST, 2004, 126 (04) : 760S - 760S
  • [8] Transition from Intravenous Epoprostenol to Treprostinil Due to Intolerable Side Effects in Patients With Pulmonary Arterial Hypertension
    Kikuchi, Hanako
    Goda, Ayumi
    Takeuchi, Kaori
    Inami, Takumi
    Kohno, Takashi
    Soejima, Kyoko
    Satoh, Toru
    AMERICAN JOURNAL OF CARDIOLOGY, 2023, 206 : 31 - 34
  • [9] Conversion From Intravenous Epoprostenol Products To Inhaled Treprostinil For Pulmonary Arterial Hypertension
    Alnuaimat, H.
    Reardon, N. T.
    Cash, J. H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [10] Thrombocytopenia in PAH patient improves with Transition from IV epoprostenol to IV treprostinil
    Mituniewicz, J.
    Rosenzweig, E. B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
12345